{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:12:55Z","timestamp":1778227975425,"version":"3.51.4"},"reference-count":56,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5,19]]},"DOI":"10.1080\/17568919.2026.2658008","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:43:27Z","timestamp":1776347007000},"page":"1239-1248","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Integrated computational and biological assessment of novel piperazine and piperidine-substituted 1,2,4-oxadiazoles for lung cancer therapy"],"prefix":"10.1080","volume":"18","author":[{"given":"Deepak","family":"Kumar","sequence":"first","affiliation":[{"name":"Nims University Rajasthan","place":["Jaipur, India"]},{"name":"Jubilant Biosys Ltd","place":["Greater Noida, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh","family":"Jangir","sequence":"additional","affiliation":[{"name":"Nims University Rajasthan","place":["Jaipur, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arti","family":"Chaurasia","sequence":"additional","affiliation":[{"name":"Devi Ahilya Vishwavidyalaya","place":["Indore, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_3_7_3_1","volume-title":"Heterocyclic chemistry","author":"Joule JA","year":"2010","unstructured":"Joule JA, Mills K. Heterocyclic chemistry. 5th ed. Chichester (UK): Wiley; 2010.","edition":"5"},{"key":"e_1_3_7_4_1","first-page":"7634","article-title":"Heterocycles in medicinal chemistry","volume":"53","author":"Katritzky AR","year":"2010","unstructured":"Katritzky AR, Pozharskii AF, Ramsden CA. Heterocycles in medicinal chemistry. J Med Chem. 2010;53:7634\u20137658.","journal-title":"J Med Chem"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501100b"},{"key":"e_1_3_7_6_1","first-page":"1252","article-title":"Bioactive heterocycles in drug discovery","volume":"12","author":"Sharma PC","year":"2021","unstructured":"Sharma PC, Bansal KK, Sharma A, et al. Bioactive heterocycles in drug discovery. RSC Med Chem. 2021;12:1252\u20131280.","journal-title":"RSC Med Chem"},{"key":"e_1_3_7_7_1","first-page":"103897","article-title":"1,2,4-oxadiazoles: synthetic and medicinal insights","volume":"100","author":"Amin KM","year":"2020","unstructured":"Amin KM, Rahman DE, Al-Eryani YA. 1,2,4-oxadiazoles: synthetic and medicinal insights. Bioorg Chem. 2020;100:103897.","journal-title":"Bioorg Chem"},{"key":"e_1_3_7_8_1","first-page":"896","article-title":"Oxadiazoles as amide bioisosteres","volume":"158","author":"Srivastava S","year":"2018","unstructured":"Srivastava S, Pandeya SN. Oxadiazoles as amide bioisosteres. Eur J Med Chem. 2018;158:896\u2013929.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_7_9_1","first-page":"228","article-title":"Medicinal properties of 12,4-oxadiazoles","volume":"23","author":"Khan I","year":"2018","unstructured":"Khan I, Ibrar A, Abbas N, et al. Medicinal properties of 12,4-oxadiazoles. Molecules. 2018;23:228.","journal-title":"Molecules"},{"key":"e_1_3_7_10_1","first-page":"1319","article-title":"Oxadiazoles in drug discovery","volume":"56","author":"Kaur R","year":"2019","unstructured":"Kaur R, Kaur J, Mahajan A, et al. Oxadiazoles in drug discovery. J Heterocycl Chem. 2019;56:1319\u20131335.","journal-title":"J Heterocycl Chem"},{"key":"e_1_3_7_11_1","first-page":"2679","article-title":"Anticancer activity of oxadiazole derivatives","volume":"21","author":"Siddiqui N","year":"2012","unstructured":"Siddiqui N, Ahuja P, Ahsan W. Anticancer activity of oxadiazole derivatives. Med Chem Res. 2012;21:2679\u20132693.","journal-title":"Med Chem Res"},{"key":"e_1_3_7_12_1","first-page":"137","article-title":"Oxadiazole hybrids with cytotoxic activity","volume":"15","author":"Sahu S","year":"2020","unstructured":"Sahu S, Mishra A, Behera RK. Oxadiazole hybrids with cytotoxic activity. ChemMedchem. 2020;15:137\u2013150.","journal-title":"ChemMedchem"},{"key":"e_1_3_7_13_1","first-page":"1209","article-title":"Biological relevance of oxadiazoles","volume":"19","author":"Lakshmi K","year":"2019","unstructured":"Lakshmi K, Reddy CS, Reddy VM. Biological relevance of oxadiazoles. Mini Rev Med Chem. 2019;19:1209\u20131228.","journal-title":"Mini Rev Med Chem"},{"key":"e_1_3_7_14_1","first-page":"127736","article-title":"Oxadiazole derivatives with antiproliferative activity","volume":"31","author":"Kar S","year":"2021","unstructured":"Kar S, Majumder R, Roy A. Oxadiazole derivatives with antiproliferative activity. Bioorg Med Chem Lett. 2021;31:127736.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_7_15_1","first-page":"3939","article-title":"Oxadiazole-based anticancer agents","volume":"25","author":"Khan S","year":"2020","unstructured":"Khan S, Ahmad K, Khan MA. Oxadiazole-based anticancer agents. Molecules. 2020;25:3939.","journal-title":"Molecules"},{"key":"e_1_3_7_16_1","first-page":"111990","article-title":"Oxadiazole hybrids as cytotoxic agents","volume":"188","author":"Mohamed MF","year":"2020","unstructured":"Mohamed MF, Abdel-Aziz HA, El-Naggar AM. Oxadiazole hybrids as cytotoxic agents. Eur J Med Chem. 2020;188:111990.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_7_17_1","first-page":"28788","article-title":"Oxadiazole hybrids in cancer research","volume":"11","author":"Rawat DS","year":"2021","unstructured":"Rawat DS, Sharma P, Sharma V. Oxadiazole hybrids in cancer research. RSC Adv. 2021;11:28788\u201328810.","journal-title":"RSC Adv"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2016.02.031"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1039\/c7ob01470h"},{"key":"e_1_3_7_20_1","first-page":"1023","article-title":"Synthetic approaches to heterocyclic bioisosteres","volume":"21","author":"Song Y","year":"2019","unstructured":"Song Y, Xu Z, Liu X. Synthetic approaches to heterocyclic bioisosteres. Org Lett. 2019;21:1023\u20131027.","journal-title":"Org Lett"},{"key":"e_1_3_7_21_1","first-page":"225","article-title":"Advances in oxadiazole synthesis","volume":"16","author":"Patel H","year":"2019","unstructured":"Patel H, Mishra R, Sharma S. Advances in oxadiazole synthesis. Curr Org Synth. 2019;16:225\u2013236.","journal-title":"Curr Org Synth"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.8b00163"},{"key":"e_1_3_7_23_1","first-page":"10994","article-title":"Therapeutic journey of piperazine","volume":"121","author":"Bansal Y","year":"2021","unstructured":"Bansal Y, Silakari O. Therapeutic journey of piperazine. Chem Rev. 2021;121:10994\u201311083.","journal-title":"Chem Rev"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules200916852"},{"key":"e_1_3_7_25_1","first-page":"8413","article-title":"Drug-like properties of nitrogen heterocycles","volume":"57","author":"Brown DG","year":"2014","unstructured":"Brown DG, Bostr\u00f6m J. Drug-like properties of nitrogen heterocycles. J Med Chem. 2014;57:8413\u20138451.","journal-title":"J Med Chem"},{"key":"e_1_3_7_26_1","first-page":"1007","article-title":"Diaminopyrimidine\u2013piperazine hybrids","volume":"138","author":"Kumar D","year":"2017","unstructured":"Kumar D, Jain SK, Yadav V. Diaminopyrimidine\u2013piperazine hybrids. Eur J Med Chem. 2017;138:1007\u20131020.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_7_27_1","first-page":"115032","article-title":"Vindoline\u2013piperazine derivatives","volume":"27","author":"Shinde G","year":"2019","unstructured":"Shinde G, Kumar D, Dalai S. Vindoline\u2013piperazine derivatives. Bioorg Med Chem. 2019;27:115032.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_7_28_1","first-page":"741","article-title":"Piperidine derivatives with anticancer activity","volume":"7","author":"Patel M","year":"2016","unstructured":"Patel M, Patel R, Patel H. Piperidine derivatives with anticancer activity. Med Chem Commun. 2016;7:741\u2013749.","journal-title":"Med Chem Commun"},{"key":"e_1_3_7_29_1","first-page":"2658","article-title":"Piperazine-based anticancer leads","volume":"57","author":"Sharma N","year":"2020","unstructured":"Sharma N, Kumar A, Sharma P. Piperazine-based anticancer leads. J Heterocycl Chem. 2020;57:2658\u20132675.","journal-title":"J Heterocycl Chem"},{"key":"e_1_3_7_30_1","first-page":"663","article-title":"EGFR in cancer therapy","volume":"21","author":"Zhang H","year":"2021","unstructured":"Zhang H, Wang Q, Murali R. EGFR in cancer therapy. Nat Rev Cancer. 2021;21:663\u2013680.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_7_31_1","first-page":"3621","article-title":"EGFR tyrosine kinase as a drug target","volume":"11","author":"Xu MJ","year":"2021","unstructured":"Xu MJ, Zhang Y, Yang J. EGFR tyrosine kinase as a drug target. Acta Pharm Sin B. 2021;11:3621\u20133643.","journal-title":"Acta Pharm Sin B"},{"key":"e_1_3_7_32_1","first-page":"278","article-title":"Structural strategies toward EGFR inhibitors","volume":"62","author":"Li X","year":"2019","unstructured":"Li X, Huang Y, Jiang Y. Structural strategies toward EGFR inhibitors. J Med Chem. 2019;62:278\u2013301.","journal-title":"J Med Chem"},{"key":"e_1_3_7_33_1","first-page":"102005","article-title":"Resistance mechanisms of EGFR inhibitors","volume":"86","author":"Gao Y","year":"2020","unstructured":"Gao Y, Arcila ME. Resistance mechanisms of EGFR inhibitors. Cancer Treat Rev. 2020;86:102005.","journal-title":"Cancer Treat Rev"},{"key":"e_1_3_7_34_1","first-page":"113665","article-title":"Hybrid EGFR inhibitors","volume":"223","author":"Wu S","year":"2021","unstructured":"Wu S, Liu S, Zhao J. Hybrid EGFR inhibitors. Eur J Med Chem. 2021;223:113665.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0306430"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030644s"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/prot.10613"},{"key":"e_1_3_7_38_1","unstructured":"Schr\u00f6dinger LLC. Schr\u00f6dinger release 2023\u20134. New York (NY); 2023."},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja9621760"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.5b00864"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-007-9133-z"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/ct200133y"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/ct100578z"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05933"},{"key":"e_1_3_7_45_1","first-page":"248","article-title":"AKT structural regulation","volume":"11","author":"Parikh C","year":"2012","unstructured":"Parikh C, Janakiraman V, Wu WI, et al. AKT structural regulation. Mol Cancer Ther. 2012;11:248\u2013259.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_7_46_1","first-page":"2070","article-title":"Structures of EGFR mutants","volume":"104","author":"Yun CH","year":"2007","unstructured":"Yun CH, Boggon TJ, Li Y, et al. Structures of EGFR mutants. Proc Natl Acad Sci USA. 2007;104:2070\u20132075.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.013"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(86)90368-6"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/51.5.1417"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910170110"},{"key":"e_1_3_7_52_1","first-page":"5481","article-title":"Lung cancer models","volume":"50","author":"Gazdar AF","year":"1990","unstructured":"Gazdar AF, Girard L, Minna JD. Lung cancer models. Cancer Res. 1990;50:5481\u20135487.","journal-title":"Cancer Res"},{"key":"e_1_3_7_53_1","first-page":"70850","article-title":"EGFR signaling in A549 cells","volume":"8","author":"Kim Y","year":"2017","unstructured":"Kim Y, Ko J, Cui Z, et al. EGFR signaling in A549 cells. Oncotarget. 2017;8:70850\u201370862.","journal-title":"Oncotarget"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1775446"},{"key":"e_1_3_7_55_1","first-page":"4453","article-title":"Oxadiazole\u2013piperazine hybrids","volume":"26","author":"Patel HM","year":"2018","unstructured":"Patel HM, Noolvi MN, Suthar M. Oxadiazole\u2013piperazine hybrids. Bioorg Med Chem. 2018;26:4453\u20134464.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_7_56_1","first-page":"493","article-title":"Heterocyclic EGFR inhibitors","volume":"178","author":"Naresh K","year":"2019","unstructured":"Naresh K, Rao PS, Reddy MV. Heterocyclic EGFR inhibitors. Eur J Med Chem. 2019;178:493\u2013507.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_7_57_1","first-page":"116728","article-title":"EGFR inhibitors in cancer therapy","volume":"60","author":"Patil SA","year":"2022","unstructured":"Patil SA, Patil R, Budagumpi S. EGFR inhibitors in cancer therapy. Bioorg Med Chem. 2022;60:116728.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_7_58_1","first-page":"5678","article-title":"Oxadiazole hybrids against lung cancer","volume":"26","author":"Alqahtani A","year":"2021","unstructured":"Alqahtani A, Khan Z, Ahmed TS, et al. Oxadiazole hybrids against lung cancer. Molecules. 2021;26:5678.","journal-title":"Molecules"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17568919.2026.2658008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:50:19Z","timestamp":1778226619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17568919.2026.2658008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,19]]}},"alternative-id":["10.1080\/17568919.2026.2658008"],"URL":"https:\/\/doi.org\/10.1080\/17568919.2026.2658008","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}